What is the role of tocilizumab in the treatment of juvenile idiopathic arthritis (JIA) in 5 or more joints?

Updated: Jul 25, 2019
  • Author: David D Sherry, MD; Chief Editor: Lawrence K Jung, MD  more...
  • Print

The US Food and Drug Administration (FDA) has approved the interleukin (IL)-6 inhibitor tocilizumab for the treatment of polyarticular JIA in children 2 years of age and older with active disease. Tocilizumab can be used alone or in combination with methotrexate. [33]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!